Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetic SignaturesASX:GSS -1.49% EV-to-EBIT is 1.18 as of Jul. 21, 2026. The stock has 4 warning signs investors should review. Among 104 Medical Diagnostics & Research companies, Genetic Signatures ranks better than 96.15% on this metric.
The historical rank and industry rank for Genetic Signatures's EV-to-EBIT or its related term are showing as below:
ASX:GSS'
s EV-to-EBIT Range Over the Past 10 Years
Min: -149.03 Med: -5.13 Max: 128.38
Current: 1.18
During the past 11 years, the highest EV-to-EBIT of Genetic Signatures was 128.38. The lowest was -149.03. And the median was -5.13.
ASX:GSS's EV-to-EBIT is ranked better than 96.15% of 104
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.7
vs ASX:GSS: 1.18
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Genetic Signatures's Enterprise Value for the quarter that ended in Dec. 2025 was A$27.47 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genetic Signatures's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-12.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Signatures EV-to-EBIT Related Terms
Genetic Signatures EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Genetic Signatures's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Genetic Signatures's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Signatures EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Genetic Signatures's EV-to-EBIT falls into.
Genetic Signatures's current Enterprise Value is A$-14.32 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genetic Signatures's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-12.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Signatures (ASX:GSS) has a EV-to-EBIT of 1.18 as of Jul. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Genetic Signatures and its competitors. According to the industry distribution chart, Genetic Signatures ranks #4 out of 104 companies in the Medical Diagnostics & Research industry, placing it in the top 3.8%.
Is Genetic Signatures' EV-to-EBIT too high?
Genetic Signatures' current EV-to-EBIT is 1.18. The Medical Diagnostics & Research industry median EV-to-EBIT is 22.70. Genetic Signatures' value of 1.18 is 94.8% below this industry median. Based on the distribution chart, Genetic Signatures ranks #4 out of 104 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Genetic Signatures' EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Signatures ranks #4 out of 104 companies for EV-to-EBIT. This places Genetic Signatures in the top 4% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 22.70. Genetic Signatures' value of 1.18 is 94.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 22.70, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetic Signatures's current EV-to-EBIT of 1.18 is 94.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Genetic Signatures and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 22.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Signatures's current EV-to-EBIT is 1.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Signatures stock overvalued right now?
Based on GuruFocus' analysis, Genetic Signatures (ASX:GSS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.38, compared to a current price of A$0.07 — trading 82.6% below its estimated fair value. The current EV-to-EBIT is 1.18 and 94.8% below the Medical Diagnostics & Research industry median of 22.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Genetic Signatures (ASX:GSS), the current EV-to-EBIT is 1.18 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genetic Signatures Ltd is a specialist molecular diagnostics company, specializing in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are based in Australia, with sales and support teams in the UK, Germany, and the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:GSS has been successfully added to your 
